tilimycin and Klebsiella-Infections

tilimycin has been researched along with Klebsiella-Infections* in 2 studies

Reviews

1 review(s) available for tilimycin and Klebsiella-Infections

ArticleYear
Klebsiella oxytoca and Emerging Nosocomial Infections.
    Current microbiology, 2021, Volume: 78, Issue:4

    Klebsiella oxytoca is rising as a significant opportunistic pathogen causing nosocomial infections in neonates as well as adults. This pathogen's prevalence varies from 2 to 24%, but outbreaks of infections due to multidrug-resistant strains can be fatal in immunocompromised individuals with comorbidities. Klebsiella oxytoca is responsible for a wide range of ailments from colitis to infective endocarditis, other than the common urinary and respiratory tract infections. The microbe's pathogenicity has been attributed to cytotoxins' production- Tilivalline and Tilimycin, in some intestinal disorders. Klebsiella oxytoca is reported to be resistant to a wide range of antibiotics. Here, we have tried to showcase a brief overview of the emergence of Klebsiella oxytoca in healthcare facilities and the nature of resistance in this species of Klebsiella.

    Topics: Adult; Bacterial Toxins; Benzodiazepines; Cross Infection; Humans; Infant, Newborn; Klebsiella; Klebsiella Infections; Klebsiella oxytoca; Pyrroles

2021

Other Studies

1 other study(ies) available for tilimycin and Klebsiella-Infections

ArticleYear
Improved molecular characterization of the
    Microbial genomics, 2021, Volume: 7, Issue:6

    Topics: Anti-Bacterial Agents; Bacterial Toxins; Benzodiazepines; Colitis; Enterocolitis, Necrotizing; Feces; Genes, Bacterial; Humans; Klebsiella Infections; Klebsiella oxytoca; Multigene Family; Prevalence; Pyrroles; Whole Genome Sequencing

2021